MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Operating Income · Q3 FY2026 · quarter ended Sep 2026
Operating income remains negative
Q3 FY2026 operating income was -$66.34M, compared with -$23.93M a year earlier. Trailing-twelve-month operating income was -$160.33M.
Context
- Operating income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -43.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$66.34M-62.1% QoQ
- Last fiscal yearDec 2025
- -$98.06M-43.8% YoY
- LTMSep 2026
- -$160.33M-76.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -177.3% | +100.0% | +277.3 pp |
| 1 year | -43.8% | +100.0% | +143.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (98.06M) USD
- Year-over-year change
- -43.8%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (98.06M) | -43.8% |
| FY2024 | 2024-12-31 | (68.19M) | -93.1% |
| FY2023 | 2023-12-31 | (35.31M) | -40.3% |
| FY2022 | 2022-12-31 | (25.16M) | — |
Operating Income vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -76.4% is the 7th highest of 8, against a peer median of +1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | €222.29M EUR | +252.5% | — | 18.4% | |
| LTM Mar 2026 | $35.9M USD | +259.6% | — | 11.4% | |
| LTM Mar 2026 | -$14.25M USD | +0.5% | — | — | |
| LTM Mar 2026 | -$66.57M USD | +49.8% | — | — | |
| LTM Mar 2026 | -$96.92M USD | +1.3% | — | 269216.7% | |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.34M USD | — | — | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$160.33M USD | -76.4% | — | — |
| LTM Sep 2026 | -$187.25M USD | -0.6% | — | 66.7% | |
| LTM Jun 2026 | -$560.02M USD | -163.1% | — | — | |
| Peer median (excluding MBX) | — | +1.3% | — | 42.5% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 248K |
| Gross Profit | 0 | 0 | 0 | (248K) |
| Gross Margin | — | — | — | — |
| Research & Development | 21.4M | 28.53M | 57.42M | 79.16M |
| Selling, General & Admin | 3.76M | 6.78M | 10.78M | 18.9M |
| Operating Expenses | 25.16M | 35.31M | 68.19M | 98.06M |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| EBITDA | (25.71M) | (32.41M) | (61.68M) | (86.72M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (25.16M) | (35.31M) | (68.19M) | (98.06M) |
| Operating Margin | — | — | — | — |
| Interest Income | 372K | 2.75M | 6.27M | 11.08M |
| Interest Expense | 374K | 0 | 0 | 0 |
| Other Income / Expenses | (974K) | 2.75M | 6.27M | 11.08M |
| Income Before Tax | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.82) | (1.02) | (1.85) | (2.38) |
| EPS (Diluted) | (0.82) | (1.02) | (1.85) | (2.38) |
| Weighted Avg Shares | 31.85M | 31.85M | 33.39M | 36.51M |
| Weighted Avg Shares (Diluted) | 31.85M | 31.85M | 33.39M | 36.51M |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.